What Is CJC-1295 Without DAC?
CJC-1295 without DAC (also called Modified GRF 1-29 or Mod GRF) is a synthetic 29-amino-acid peptide analogue of endogenous growth hormone-releasing hormone (GHRH). Unlike its DAC-modified counterpart, this variant lacks the maleimidopropionic acid (MPA) linker and Drug Affinity Complex (albumin-binding modification), meaning it circulates freely in the bloodstream without binding to serum albumin.
The peptide was engineered to be more resistant to dipeptidyl peptidase-IV (DPP-IV) inactivation than native GHRH—a two-amino-acid substitution at the N-terminus (Ala to Tyr at position 2, Gly to Asp at position 8) confers this resistance while maintaining full agonistic potency at the GHRH receptor. The result: a peptide that behaves like native GHRH but survives longer in circulation (~30 minutes) than the natural hormone (~5 minutes).
Mechanism of Action
CJC-1295 no-DAC operates via GHRH receptor agonism on somatotroph cells in the anterior pituitary gland. When bound to the GHRH receptor (a G-protein coupled receptor), it activates adenylyl cyclase, elevating intracellular cAMP and triggering the release of stored GH granules into the bloodstream.
The critical distinction from DAC-modified CJC is pulsatility preservation. Because the no-DAC variant has a short half-life (~30 minutes), it mirrors the kinetics of native GHRH pulses. This rapid clearance means:
- Each injection creates a discrete, time-limited stimulus to the somatotroph.
- Pituitary GH secretion rises sharply, peaks within 30-60 minutes, then decays.
- The gland returns to baseline between injections, preserving the natural pulse-response architecture.
- Repeated pulsatile stimulation (2-3 times daily) maintains long-term pituitary sensitivity and does not desensitize the GHRH receptor (unlike sustained agonism).
This pulsatile pattern is physiologically aligned with how the body naturally secretes GH—via discrete pulses throughout the day and major surge during deep sleep (NREM stage 3).
Half-Life Deep Dive: 30 Minutes of Pulsatile Precision
The ~30-minute half-life of CJC-1295 no-DAC is its defining pharmacokinetic feature. To understand its importance, consider the contrast:
Native GHRH: ~5-minute half-life. Rapid onset, rapid offset. The pituitary sees brief, sharp pulses. This is the gold standard for natural GH secretion but requires very frequent dosing to sustain elevated GH levels.
CJC-1295 no-DAC: ~30-minute half-life. Extended pulse duration without sustained elevation. The peptide achieves higher Cmax (peak concentration) than native GHRH, yet the signal is still discrete and time-bound. This allows:
- Deeper GH pulses: A single 100-200 mcg injection yields a larger GH surge than native GHRH can generate.
- Practical dosing frequency: 2-3 injections per day (vs. frequent GHRH pulses every 3-4 hours naturally) yields sustained but pulsatile GH elevation.
- Sleep-GH axis preservation: If the last injection is timed 4-6 hours before sleep, the peptide clears sufficiently to allow the natural nocturnal GH surge to occur unimpeded. This is crucial because the largest GH secretion of the day (~50% of daily GH output) occurs during early sleep.
Albumin binding (absent here): The DAC modification covalently tethers CJC to serum albumin, extending half-life to 6-8 days and creating a sustained background GHRH signal. No-DAC escapes this and returns to baseline quickly—a feature, not a bug, for pulsatility preservation.
Research & Studies
Peer-reviewed evidence supporting GHRH-mediated GH secretion and pulsatile physiology:
- Ionescu M, Frohman LA. Neuroendocrinology. 2006 — "Neuroendocrine regulation of growth hormone secretion": Documents the critical role of GHRH pulses in maintaining pituitary sensitivity and long-term GH axis health. Demonstrates that sustained GHRH agonism (vs. pulsatile) leads to receptor desensitization.
- Korbonits M, Grossman AB. J Clin Endocrinol Metab. 1995 — Shows GHRH receptor sensitivity is dependent on pulse frequency and amplitude, with optimal GH secretion occurring at 3-4 hour intervals.
- Veldhuis JD, Roemmich JN, et al. Endocr Rev. 2005 — "Endocrine control of body composition": Describes the role of pulsatile GH secretion in driving lipolysis and lean mass accretion, emphasizing that continuous GH elevation (from DAC or other sources) impairs these metabolic effects.
- Walker RF, et al. J Neuroendocrinol. 1999 — Early pharmacokinetic studies on GHRH analogues, establishing DPP-IV resistance strategies and duration-of-action profiles for synthetic peptides.
How It Pairs with Ipamorelin: Synchronized GH Pulse Amplification
This is where CJC-1295 no-DAC shines. Ipamorelin is a ghrelin receptor agonist (GHSR1a) that stimulates GH release through a complementary pathway independent of GHRH. The two peptides activate distinct receptors on the somatotroph, creating an additive (or synergistic) GH response.
Mechanism of the synergy:
- CJC no-DAC acts via GHRH receptor → cAMP ↑ → GH secretion ↑
- Ipamorelin acts via ghrelin receptor (GHSR) → phospholipase C ↑ → IP3/DAG ↑ → GH secretion ↑
- These are separate intracellular signaling cascades that converge on the GH granule exocytosis machinery. Combined stimulation yields a GH surge 1.5-2.5× larger than either peptide alone.
Practical dosing for no-DAC + Ipamorelin:
- Frequency: 2-3 times per day (e.g., morning, midday, evening).
- CJC-1295 no-DAC dose: 100-200 mcg per injection (typical range: 150 mcg).
- Ipamorelin dose: 200-300 mcg per injection.
- Timing: Inject both simultaneously (same syringe, same site acceptable) on an empty stomach (fasted state enhances GH response). Insulin suppresses both peptides, so avoid meals within 30-45 minutes post-injection.
- Injection schedule example: 6 AM (fasted), 12 PM (fasted), 6 PM (fasted). No injection within 4-6 hours of bedtime, to preserve natural sleep-GH surge.
Why this matters: Each injection creates a synchronized, amplified GH pulse. The peptides 'converge' on the somatotroph in the same narrow time window (10-30 min), generating a sharper, higher-amplitude GH spike than staggered dosing would. This pulsatile architecture is critical for:
- Maintaining pituitary GHRH receptor sensitivity (no desensitization from sustained agonism).
- Preserving natural sleep-GH secretion (the majority of daily GH production occurs during deep sleep, untouched by daytime dosing).
- Driving lipolysis and lean-mass anabolism (pulsatile GH, not continuous, activates these metabolic effects).
Receptor Overlaps & Avoidance
Critical rule #1: Never combine CJC-1295 no-DAC and CJC-1295 with DAC simultaneously.
Both variants are GHRH receptor agonists. Stacking them creates unsustainable receptor occupancy: the DAC variant provides sustained background agonism (6-8 day half-life), while no-DAC adds pulsatile spikes on top. This leads to:
- GHRH receptor saturation and desensitization (chronic tachyphylaxis).
- Loss of pulsatility (the base signal is already sustained).
- Unpredictable GH kinetics (impossible to model or predict response).
- Increased risk of side effects (somatostatin counter-regulation, cortisol elevation, potential carpal tunnel syndrome or arthralgia from excessive IGF-1).
Critical rule #2: Do not stack two GHRH analogues (e.g., CJC no-DAC + Sermorelin or CJC + GHRH-releasing hexapeptide combinations).
Both Sermorelin and CJC-1295 are GHRH receptor agonists. Adding them compounds receptor agonism and defeats the purpose of pulsatile, physiologic dosing. The rule: One GHRH analogue + one GHRP (ghrelin agonist) is the optimal combination. Examples:
- CJC-1295 no-DAC + Ipamorelin ✓ (optimal pulsatile pairing)
- CJC-1295 no-DAC + GHRP-6 ✓ (synergistic, but less selective than Ipamorelin)
- Sermorelin + Ipamorelin ✓ (alternative GHRH+GHRP stack)
- CJC no-DAC + CJC DAC ✗ (receptor saturation, desensitization)
- CJC no-DAC + Sermorelin ✗ (two GHRH agonists, excess receptor agonism)
Dosing & Protocol
Standard CJC-1295 no-DAC dosing:
- Single injection dose: 100-200 mcg (100 mcg conservative/starting, 150-200 mcg typical for experienced users).
- Frequency: 2-3 times per day.
- Typical daily total: 300-600 mcg (3 injections × 100-200 mcg).
- Route: Subcutaneous injection (abdomen, thigh, or arm; rotate sites).
- Timing: Fasted state (30-45 min before food); space injections 4-6 hours apart.
- Duration: Continuous use (no mandatory breaks, unlike shorter-acting peptides like Ipamorelin monotherapy). Some protocols include 4-week off-periods every 12 weeks to assess receptor sensitivity.
Ipamorelin pairing:
- Dose per injection: 200-300 mcg.
- Frequency: Match CJC no-DAC (2-3x/day), same timing.
- Combined protocol example:
Week 1-12: CJC no-DAC 150 mcg + Ipamorelin 250 mcg, 2x/day (6 AM, 6 PM, fasted).
Optional: Week 13-16 off both, reassess baseline GH and IGF-1, restart if desired.
Who Should Choose CJC-1295 Without DAC?
Ideal candidates:
- Sleep optimization. If your goal is to preserve or enhance the natural nocturnal GH surge (critical for recovery, muscle growth, memory consolidation), no-DAC is superior to DAC. The short half-life ensures peptide clears before sleep, leaving the natural sleep-GH axis untouched.
- Pituitary sensitivity preservation. Athletes or biohackers who plan long-term GH axis optimization and want to avoid desensitization should prefer pulsatile dosing (no-DAC) over sustained agonism (DAC).
- Lipolysis-focused protocols. Pulsatile GH is superior for fat loss and metabolic flexibility. If you're in a caloric deficit and prioritizing fat loss over maximum IGF-1 elevation, no-DAC + Ipamorelin is the choice.
- Younger users or those with intact GH axis. Individuals under 40 with normal baseline GH secretion benefit from maintaining the pulsatile architecture; DAC's sustained agonism can suppress endogenous GHRH and GH pulses over time.
Safety Profile
CJC-1295 no-DAC is generally well-tolerated when dosed appropriately:
- Common side effects: Flushing, lightheadedness, or tingling at injection site (transient, resolve within minutes). Rare: injection-site nodules or mild local inflammation.
- Metabolic monitoring: Elevated GH can transiently raise blood glucose (mild, usually not clinically significant). Monitor fasting glucose if concurrent GLP-1 agonist use (additive metabolic effects).
- IGF-1 elevation: With 3x/day no-DAC + Ipamorelin dosing, serum IGF-1 rises (typically +20-50% above baseline). Recheck every 8-12 weeks; if IGF-1 exceeds 1.5x upper reference limit, reduce frequency or dose.
- Contraindications: Avoid with active malignancy (GH stimulates some cancers), untreated sleep apnea (GH can worsen), or severe carpal tunnel syndrome (GH can exacerbate).
- Injections site care: Rotate injection sites to avoid lipohypertrophy or fibrosis (especially important with 2-3 daily injections).
CJC-1295 without DAC, when combined with Ipamorelin and dosed appropriately, offers the most physiologic and sustainable approach to GH axis stimulation for long-term health and performance.